Sodium glucose co-transporter 2 (SGLT2) inhibitors have also proven efficacious in regulating NAFLD-associated dyslipidemia by inhibiting hepatic expression of lipogenic genes (e.g., sterol regulatory-element binding protein 1-c, fatty acid synthase, acetyl-CoA carboxylase 1, and sterol CoA desaturase), hepatic macrophage infiltration and expression of inflammatory cytokine production (190, 193, 194). Here, FASN is linked to metabolic dysfunction-associated steatotic liver disease.